Compare AstraZeneca plc (AZN) vs iShares MSCI Indonesia ETF (EIDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs iShares MSCI Indonesia ETF — how do they compare? AstraZeneca plc trades at $166.95 (market cap $258.17B), while iShares MSCI Indonesia ETF trades at $12. The key difference: AstraZeneca plc pays a 1.87% dividend while iShares MSCI Indonesia ETF pays none, and AstraZeneca plc is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals.
| AZN | EIDO | |
|---|---|---|
Market Cap | $258.17B | — |
Sector | Health | — |
52-Week High | $209.48 | $19.22 |
52-Week Low | $137.44 | $10.80 |
Enterprise Value | $284.41B | — |
Dividend Yield | 1.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
EIDO, the iShares MSCI Indonesia ETF, trades at $11.98, up 1.1% on the day, but technical indicators signal a bearish trend with moving averages and RSI_6 suggesting caution. Key financial ratios are unavailable, but recent news highlights Indonesia's economic initiatives, including a $15 billion AI-integrated free-meal program and central bank rate hikes to support the rupiah. The ETF's dividend dropped 27% in 2025, indicating potential income instability for investors.
The outlook for EIDO is mixed, with opportunities from Indonesia's GDP growth potential but risks from currency volatility and dividend cuts. Investors face headwinds from bearish technical signals and macroeconomic pressures, requiring careful assessment of emerging market exposure amid fluctuating sentiment and limited fundamental data.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →
